Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients.
Recombinant human erythropoietin (r-HuEPO) was given to 51 maintenance hemodialysis patients in an attempt to correct the anemia of uremia. A subset of eight randomly chosen stable patients (four men and four women, mean age 42.3 years) had in vivo urea and creatinine dialyzer clearances measured before and after their hematocrits were increased by r-HuEPO treatment. The same dialyzer was used in both the pre-r-HuEPO and post-r-HuEPO studies. Dialyzer creatinine (Ccr) and urea (Ucr) clearances were measured at a blood flow of 300 ml/min 1 hour after the initiation of dialysis. The mean hematocrit of the group of 51 patients increased from 19% (range, 14-28%) to 33% (range, 21-27%). The mean hematocrit of the eight patients in whom the clearance studies were done was 19% before r-HuEPO and 35% after. Mean creatinine and urea clearances for the eight subjects at the lower hematocrit were 143 and 190 ml/min, respectively. After the increase in hematocrit, the mean creatinine and urea clearances were slightly lower at 132 and 166 ml/min, respectively. No patient had a rise in predialysis serum potassium, creatinine, or blood urea nitrogen. The authors concluded that the magnitude of changes in creatinine and urea clearances secondary to a r-HuEPO stimulated rise in hematocrit will be small and will not necessitate increases in dialysis time.